EU Critical Medicines Act: Parliament Clarifies ‘Significant Proportion’ Rule

 
• By Eliza Slawther
  
Companies that manufacture a significant amount of critical medicines in the EU will be favored when it comes to procurement contracts

More from Manufacturing

More from Compliance